At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of diffuse large B-cell non-Hodgkin's lymphoma at bulky stage II, stage III, or stage IV
- ✓CD20 antigen-positive disease confirmed
- ✓Bidimensionally measurable disease present
- ✓Circulating lymphoid cells <20,000/mcL on WBC differential
- ✕Prior antibody therapy for lymphoma
- ✕Prior chemotherapy for lymphoma
- ✕Prior radiotherapy for lymphoma
- ✕Clinical evidence of CNS involvement by lymphoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study
In Brief
A Phase 2 clinical trial evaluating rituximab, cyclophosphamide, and 4 other interventions for Lymphoma. Completed, enrolled 86 participants across 78 sites.
Detailed Summary
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving a radiolabeled monoclonal antibody together with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving iodine I 131 tositumomab together with rituximab and combination chemotherapy works in treating older patients with stage II, stage III, or stage IV B-cell non-Hodgkin's lymphoma.